Author

Marcia L. Craib

Observed names: M. Craib, Marcia Craib

Observed institutions: Pfizer (United States), Genentech, Clovis Oncology (United States), Appalachian State University

OpenAlex ID: A5055208758

Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis

2007 · Michael W. Konstan, Wayne J. Morgan, et al. · The Journal of Pediatrics · 438

Risk factors for mortality before age 18 years in cystic fibrosis

2017 · Susanna A. McColley, Michael S. Schechter, et al. · Pediatric Pulmonology · 94

Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change

2017 · Donald R. VanDevanter, Marcia L. Craib, et al. · Pediatric Pulmonology · 10

Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study

2025 · R.S. Kristeleit, S. Ghamande, et al. · Annals of Oncology · 7

Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.

2024 · David M. O'Malley, Bradley J. Monk, et al. · Journal of Clinical Oncology · 5

Interim post-progression data and updated survival in patients with newly diagnosed advanced ovarian cancer in ATHENA-MONO

2024 · Rebecca Kristeleit, David O'Malley, et al. · Gynecologic Oncology · 3

LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes

2025 · Sriram Anbil, Nicholas J. Seewald, et al. · JCO Precision Oncology · 2

Elevated Serum Cytokines Associated With Plantar Fasciitis

1999 · C. Rananto, E. Hogen, et al. · Medicine & Science in Sports & Exercise · 1

Patients With Newly Diagnosed Advanced Ovarian Cancer in Athena-mono/gog-3020/engot-ov45: Subsequent Anti-cancer Therapy by Hrd Status

2026 · Diane Provencher, Mark Messing, et al. · International Journal of Gynecological Cancer

Impact of prior treatment setting on the efficacy of rucaparib vs physician’s choice in BRCA -mutated castration-resistant prostate cancer (mCRPC) in TRITON3.

2026 · Srikala S. Sridhar, Karim Olivier Fizazi, et al. · Journal of Clinical Oncology

Safety of Rucaparib Monotherapy in Advanced High-grade Ovarian Cancer Clinical Trials

2025 · Domenica Lorusso, Lainie Martin, et al. · International Journal of Gynecological Cancer

LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes.

2025 · Sriram Anbil, Nicholas Seewald, et al. · Journal of Clinical Oncology

ATHENA-MONO Post-Progression Survival Data Update In Patients With Newly Diagnosed Advanced Ovarian Cancer

2025 · Sharad Ghamande, Rowan E. Miller, et al. · International Journal of Gynecological Cancer

Abstract C006: LODESTAR: A Single Arm Phase II Study of Rucaparib in Solid Tumors with Pathogenic Germline or Somatic Variants in Homologous Recombination Repair (HRR) Genes

2024 · Sriram Anbil, Nicholas J Seewald, et al. · Cancer Research

176 Rucaparib maintenance treatment in patients (Pts) with newly diagnosed ovarian cancer (OC): defining benefit according to disease risk subgroups within the phase 3 ATHENA-MONO study

2024 · Domenica Lorusso, Rebecca S. Kristeleit, et al. · International Journal of Gynecological Cancer

Works count: 15

Citation count: 560

H-index: 5

I10-index: 3